Matt Phipps
Stock Analyst at William Blair
(1.18)
# 3,772
Out of 5,115 analysts
25
Total ratings
41.18%
Success rate
-6.57%
Average return
Main Sectors:
Stocks Rated by Matt Phipps
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DVAX Dynavax Technologies | Downgrades: Market Perform | n/a | $15.38 | - | 1 | Dec 24, 2025 | |
| EVMN Evommune | Initiates: Outperform | n/a | $17.59 | - | 1 | Dec 1, 2025 | |
| KZR Kezar Life Sciences | Downgrades: Market Perform | n/a | $6.36 | - | 3 | Oct 17, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | n/a | $4.89 | - | 1 | Oct 16, 2025 | |
| INSM Insmed | Initiates: Outperform | n/a | $177.42 | - | 1 | Aug 20, 2025 | |
| INKT MiNK Therapeutics | Downgrades: Market Perform | n/a | $11.90 | - | 2 | Jul 14, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | n/a | $1.83 | - | 2 | Jul 7, 2025 | |
| CNTX Context Therapeutics | Initiates: Outperform | n/a | $1.15 | - | 1 | Apr 21, 2025 | |
| XNCR Xencor | Initiates: Outperform | n/a | $15.45 | - | 1 | Apr 21, 2025 | |
| GMAB Genmab | Upgrades: Outperform | n/a | $33.72 | - | 2 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $21.36 | - | 1 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $30.27 | - | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.55 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.26 | - | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $54.71 | - | 1 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.31 | - | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.07 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $176.33 | - | 2 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $96.91 | - | 1 | Apr 8, 2021 |
Dynavax Technologies
Dec 24, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $15.38
Upside: -
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: n/a
Current: $17.59
Upside: -
Kezar Life Sciences
Oct 17, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $6.36
Upside: -
Climb Bio
Oct 16, 2025
Initiates: Outperform
Price Target: n/a
Current: $4.89
Upside: -
Insmed
Aug 20, 2025
Initiates: Outperform
Price Target: n/a
Current: $177.42
Upside: -
MiNK Therapeutics
Jul 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $11.90
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.83
Upside: -
Context Therapeutics
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $1.15
Upside: -
Xencor
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $15.45
Upside: -
Genmab
Mar 11, 2025
Upgrades: Outperform
Price Target: n/a
Current: $33.72
Upside: -
Dec 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $21.36
Upside: -
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $30.27
Upside: -
Sep 30, 2024
Initiates: Outperform
Price Target: n/a
Current: $12.55
Upside: -
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $10.26
Upside: -
Oct 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $54.71
Upside: -
Nov 14, 2022
Initiates: Outperform
Price Target: n/a
Current: $14.31
Upside: -
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.07
Upside: -
Jun 8, 2021
Upgrades: Outperform
Price Target: n/a
Current: $176.33
Upside: -
Apr 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $96.91
Upside: -